(2024) Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1). Innovative Medicine of Kuban. pp. 126-135. ISSN 25419897 (ISSN)
Full text not available from this repository.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes. © 2024 Scientific Research Institute — Ochapovsky Clinical Regional Hospital no. 1. All rights reserved.
Item Type: | Article |
---|---|
Keywords: | cardioprotection dapagliflozin empagliflozin nephroprotection SGLT2i |
Page Range: | pp. 126-135 |
Journal or Publication Title: | Innovative Medicine of Kuban |
Journal Index: | Scopus |
Volume: | 9 |
Number: | 4 |
Identification Number: | https://doi.org/10.35401/2541-9897-2024-9-4-126-135 |
ISSN: | 25419897 (ISSN) |
Depositing User: | خانم ناهید ضیائی |
URI: | http://eprints.mui.ac.ir/id/eprint/30753 |
Actions (login required)
![]() |
View Item |